What the six lenses say about NATCOPHARM — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.
How NATCOPHARM’s own sector index is moving — context for reading the stock’s six lenses.
Six-lens read
The actual numbers
The actual numbers
Full 8-quarter history in the financials table below.
The actual numbers
The actual numbers
Every filing in the corporate-announcements panel below.
The actual numbers
Decile — each lens’s 0–100 score is ranked against every Small-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.
Conviction — the average of the two active conviction-lens deciles (Technical & Flow):
Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.
Glass box
Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.
Policy
Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.
PLI Scheme — Pharmaceuticals & API
Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices
Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-07-10.
| Baseline | 1D | 1W | 1M | 3M | 6M | 12M |
|---|---|---|---|---|---|---|
Nifty 50 Large-cap anchor | -0.8pp | +3.8pp | +9.3pp | -12.5pp | +14.7pp | +1.8pp |
Nifty 500 Broad-market baseline | -1.2pp | +3.7pp | +8.7pp | -16.2pp | +9.7pp | -2.0pp |
Sector Own-sector index | — | — | +7.0pp | -27.8pp | -3.1pp | -16.5pp |
From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).
Trend
NATCOPHARM daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.
Relative strength
NATCOPHARM ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.
TradingView composite technical analysis — multi-timeframe consensus
Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.
| Metric | Jun '24 | Sep '24 | Dec '24 | Mar '25 | Jun '25 | Sep '25 | Dec '25 | Mar '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue (₹cr) | 1,363 | 1,371 | 475 | 1,221 | 1,329 | 1,363 | 647 | 739 |
| ↳ change QoQ | — | +0.6% | -65.4% | +157.2% | +8.8% | +2.6% | -52.5% | +14.2% |
| EBITDA (₹cr) | 853 | 868 | 215 | 548 | 571 | 579 | 159 | 128 |
| EBITDA margin | 62.6% | 63.3% | 45.3% | 44.9% | 43.0% | 42.5% | 24.6% | 17.3% |
| PAT (₹cr) | 669 | 677 | 132 | 406 | 480 | 518 | 151 | 269 |
| ↳ change QoQ | — | +1.2% | -80.4% | +206.6% | +18.2% | +7.9% | -70.8% | +78.1% |
| Net margin | 49.1% | 49.3% | 27.9% | 33.3% | 36.1% | 38.0% | 23.3% | 36.4% |
| EPS (₹) | 37.32 | 37.81 | 7.43 | 22.70 | 26.84 | 28.94 | 8.46 | 14.96 |
| D/E | — | — | — | — | — | — | — | — |
Filings to the exchange — capital actions, earnings and governance. Most recent first.
A governance / disclosure filing — lower signal weight, context only.
View original filing on NSE ↗An exchange filing — open the original disclosure on NSE for the full text.
View original filing on NSE ↗A governance / disclosure filing — lower signal weight, context only.
View original filing on NSE ↗A governance / disclosure filing — lower signal weight, context only.
View original filing on NSE ↗An exchange filing — open the original disclosure on NSE for the full text.
View original filing on NSE ↗A governance / disclosure filing — lower signal weight, context only.
View original filing on NSE ↗A governance / disclosure filing — lower signal weight, context only.
View original filing on NSE ↗A governance / disclosure filing — lower signal weight, context only.
View original filing on NSE ↗An exchange filing — open the original disclosure on NSE for the full text.
View original filing on NSE ↗An exchange filing — open the original disclosure on NSE for the full text.
View original filing on NSE ↗A governance / disclosure filing — lower signal weight, context only.
View original filing on NSE ↗An exchange filing — open the original disclosure on NSE for the full text.
View original filing on NSE ↗A governance / disclosure filing — lower signal weight, context only.
View original filing on NSE ↗A governance / disclosure filing — lower signal weight, context only.
View original filing on NSE ↗A governance / disclosure filing — lower signal weight, context only.
View original filing on NSE ↗…and 5 more.
Ownership
Mutual funds holding NATCOPHARM (6)
| Fund | Weight | AUM ₹cr | Grade |
|---|---|---|---|
| Sundaram Small Cap Gr | 1.58% | 3,681 | |
| Capitalmind Flexi Cap Reg Gr | 2.32% | 431 | |
| Samco Flexi Cap Reg Gr | 2.97% | 283 | |
| Samco Multi Cap Reg Gr | 1.05% | 243 | |
| The Wealth Company Flexi Cap Reg Gr | 1.75% | 231 | |
| Samco Small Cap Reg Gr | 1.29% | 151 |
ETFs holding NATCOPHARM (3)
| ETF | Weight | Grade |
|---|---|---|
| Zerodha Nifty Smallcap 100 ETF | 0.84% | |
| Mirae Asset Nifty 500 Healthcare ETF | 0.72% | |
| Motilal Oswal BSE Healthcare ETF | 0.62% |